Coloplast 将来の成長

Future 基準チェック /36

Coloplastは、11%と7.7%でそれぞれ年率11%で利益と収益が成長すると予測される一方、EPSはgrowで11.2%年率。

主要情報

11.0%

収益成長率

11.2%

EPS成長率

Medical Equipment 収益成長	0%
収益成長率	7.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	18 May 2023

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:0QBO N - アナリストの将来予測と過去の財務データ ( )DKK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2025	28,820	6,541	6,167	7,542	14
9/30/2024	26,707	5,885	5,587	6,879	17
9/30/2023	24,748	5,107	4,809	6,220	18
3/31/2023	24,074	4,801	3,663	4,894	N/A
12/31/2022	23,515	4,626	3,246	4,455	N/A
9/30/2022	22,579	4,706	3,964	5,099	N/A
6/30/2022	21,620	4,781	3,894	4,913	N/A
3/31/2022	20,606	4,746	3,735	4,712	N/A
12/31/2021	19,857	4,896	4,272	5,209	N/A
9/30/2021	19,426	4,825	3,324	5,290	N/A
6/30/2021	18,916	4,561	3,102	5,023	N/A
3/31/2021	18,500	4,304	3,162	5,077	N/A
12/31/2020	18,570	4,241	3,003	4,941	N/A
9/30/2020	18,544	4,197	3,828	4,759	N/A
6/30/2020	18,572	3,949	3,876	4,842	N/A
3/31/2020	18,752	4,020	3,872	4,764	N/A
12/31/2019	18,330	3,974	3,833	4,615	N/A
9/30/2019	17,939	3,873	3,667	4,357	N/A
6/30/2019	17,555	4,119	3,599	4,161	N/A
3/31/2019	17,181	3,999	3,562	4,177	N/A
12/31/2018	16,815	3,896	3,522	4,126	N/A
9/30/2018	16,449	3,845	3,692	4,361	N/A
6/30/2018	16,195	3,816	3,587	4,370	N/A
3/31/2018	15,882	3,778	3,361	4,111	N/A
12/31/2017	15,728	3,791	3,235	4,004	N/A
9/30/2017	15,528	3,797	2,566	3,251	N/A
6/30/2017	15,287	3,211	2,308	2,994	N/A
3/31/2017	15,061	3,279	1,808	2,492	N/A
12/31/2016	14,780	3,264	N/A	2,653	N/A
9/30/2016	14,681	3,143	N/A	3,028	N/A
6/30/2016	14,563	1,297	N/A	3,081	N/A
3/31/2016	14,417	1,028	N/A	3,568	N/A
12/31/2015	14,264	927	N/A	3,320	N/A
9/30/2015	13,909	899	N/A	3,337	N/A
6/30/2015	13,502	3,162	N/A	3,119	N/A
3/31/2015	13,096	3,241	N/A	3,015	N/A
12/31/2014	12,666	2,407	N/A	3,193	N/A
9/30/2014	12,428	2,390	N/A	3,149	N/A
6/30/2014	12,184	2,298	N/A	3,177	N/A
3/31/2014	12,008	2,220	N/A	3,074	N/A
12/31/2013	11,833	2,874	N/A	3,270	N/A
9/30/2013	11,635	2,711	N/A	3,136	N/A
6/30/2013	11,514	2,570	N/A	2,912	N/A
3/31/2013	11,384	2,448	N/A	2,907	N/A
12/31/2012	11,234	2,327	N/A	2,894	N/A
9/30/2012	11,023	2,194	N/A	2,649	N/A
6/30/2012	10,745	2,117	N/A	2,686	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0QBO Nの予測収益成長率 (年間11% ) は貯蓄率 ( 7.6% ) を上回っています。

収益対市場: 0QBO Nの収益 ( 11% ) はMX市場 ( 11.3% ) よりも速いペースで成長すると予測されています。

高成長収益: 0QBO Nの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 0QBO Nの収益 ( 7.7% ) MX市場 ( 7.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0QBO Nの収益 ( 7.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0QBO Nの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Coloplast 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘